arrow
J

Jang-Ho Bae

Mayo Clinic
H指数:32
被引数:5,061

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease

多支血管冠状动脉疾病中,血管内超声引导的经皮冠状动脉介入治疗与冠状动脉旁路移植术的长期结局比较

HEART
IF4.4
2025-05-140
PRE
Optical Coherence Tomography-Guided or Intravascular Ultrasound-Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial
2023-10-1746
PRE
Comparison of 2-year mortality according to obesity in stabilized patients with type 2 diabetes mellitus after acute myocardial infarction: results from the DIAMOND prospective cohort registry (vol 14, 141, 2015)
2023-06-290
OAAI
Association of Intima-Media Thickness Measured at the Common Carotid Artery With Incident Carotid Plaque: Individual Participant Data Meta-Analysis of 20 Prospective Studies

颈总动脉内中膜厚度与新发颈动脉斑块的相关性:20项前瞻性研究的个体参与者数据荟萃分析

2023-06-203
OAAI
Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention
2023-04-0115
OAAI
Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Outcomes of Multicenter Randomized Controlled BEST Trial
2022-11-2218
OA
Effects of Prolonged Dual Antiplatelet Therapy in ST-Segment Elevation vs. Non-ST-Segment Elevation Myocardial Infarction
2021-05-251
OA
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial
2020-08-25270
OAAI
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients
2020-08-18300
OAAI
The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale
2020-07-012
OAAI
Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention An Analysis From the SMART-DATE Randomized Trial
2020-05-0132
OAAI
Effect of Operator Volume on In-Hospital Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Based on the 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry
2020-01-017
OAAI
Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study

替米沙坦和瑞舒伐他汀固定剂量联合治疗韩国高血压和血脂异常患者的疗效和安全性: TELSTA-YU (来自YUhan的替米沙坦-瑞舒伐他汀),一项多中心,随机,4组,双盲,安慰剂对照,III期研究

2018-05-0123
PREAI
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
LANCET
IF88.5
2018-03-01274
PREAI